AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

March 15, 2018

Responsive image

LONDON and PHILADELPHIA, March 15, 2018 /PRNewswire/ — AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options, today announced the presentation of final data…

Category: Precious Metals